Serum angiopoietin‐2 levels predict regression of Mac‐2 binding protein glycosylation isomer‐based liver fibrosis after hepatitis C virus eradication by direct‐acting antiviral agents
Aim It is desirable to identify predictors of regression of liver fibrosis after achieving a sustained virologic response (SVR) by direct‐acting antiviral agents (DAAs) to antihepatitis C virus (HCV) therapy. Here, we retrospectively investigated the serum angiopoietin‐2 (Ang‐2) level as a predictiv...
Gespeichert in:
| Veröffentlicht in: | Hepatology research 2022-11, Vol.52 (11), p.919-927 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 927 |
|---|---|
| container_issue | 11 |
| container_start_page | 919 |
| container_title | Hepatology research |
| container_volume | 52 |
| creator | Suzuki, Takanori Matsuura, Kentaro Nagura, Yoshihito Ogawa, Shintaro Fujiwara, Kei Nojiri, Shunsuke Watanabe, Takehisa Kataoka, Hiromi Tanaka, Yasuhito |
| description | Aim
It is desirable to identify predictors of regression of liver fibrosis after achieving a sustained virologic response (SVR) by direct‐acting antiviral agents (DAAs) to antihepatitis C virus (HCV) therapy. Here, we retrospectively investigated the serum angiopoietin‐2 (Ang‐2) level as a predictive indicator of regression of liver fibrosis after successful HCV eradication by DAA therapy.
Methods
The study subjects were recruited from a historical cohort of 109 chronically HCV‐infected patients who had achieved SVR by DAA therapy and whose serum Mac‐2 binding protein glycosylation isomer (M2BPGi) levels at baseline (before DAA therapy) were ≥2.0 the cut‐off index (COI). We defined patients with M2BPGi levels |
| doi_str_mv | 10.1111/hepr.13823 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2699960502</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2729401493</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3543-9271feca329745282a9a7160946b3970feb5b29fcb7649044ae741338f6a98db3</originalsourceid><addsrcrecordid>eNp90c1u1DAQAOAIUYnScuEJLHFBSCn-2zg-olVLkYqo-JG4WY4zDq689mI7i3LjEXgj3oUnwdtw6gFf7JE-z4w9TfOc4AtS1-tvsE8XhPWUPWpOSS9oixn_-rieWd-1HePdk-ZpzncYE4EpP21-f4I075AOk4v76KC48OfnL4o8HMBntE8wOlNQgilBzi4GFC16r809GlwYXZiqigVcQJNfTMyL1-UIXY47SBUOOsOIvDtAQtYNKWaXkbalhrXfikuNt-jg0pwRJF0rrhmGBY0ugSk1iTblWEqH4irUHukJQsnnzYnVPsOzf_tZ8-Xq8vP2ur358Pbd9s1Na9iGs1ZSQSwYzagUfEN7qqUWpMOSdwOTAlsYNgOV1gyi4xJzrkFwwlhvOy37cWBnzcs1b33r9xlyUTuXDXivA8Q5K9pJKTu8wbTSFw_oXZxTqN0pKqjkmHDJqnq1KlP_Iyewap_cTqdFEayOs1THWar7WVZMVvzDeVj-I9X15e3H9c5f_CGphg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2729401493</pqid></control><display><type>article</type><title>Serum angiopoietin‐2 levels predict regression of Mac‐2 binding protein glycosylation isomer‐based liver fibrosis after hepatitis C virus eradication by direct‐acting antiviral agents</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Suzuki, Takanori ; Matsuura, Kentaro ; Nagura, Yoshihito ; Ogawa, Shintaro ; Fujiwara, Kei ; Nojiri, Shunsuke ; Watanabe, Takehisa ; Kataoka, Hiromi ; Tanaka, Yasuhito</creator><creatorcontrib>Suzuki, Takanori ; Matsuura, Kentaro ; Nagura, Yoshihito ; Ogawa, Shintaro ; Fujiwara, Kei ; Nojiri, Shunsuke ; Watanabe, Takehisa ; Kataoka, Hiromi ; Tanaka, Yasuhito</creatorcontrib><description>Aim
It is desirable to identify predictors of regression of liver fibrosis after achieving a sustained virologic response (SVR) by direct‐acting antiviral agents (DAAs) to antihepatitis C virus (HCV) therapy. Here, we retrospectively investigated the serum angiopoietin‐2 (Ang‐2) level as a predictive indicator of regression of liver fibrosis after successful HCV eradication by DAA therapy.
Methods
The study subjects were recruited from a historical cohort of 109 chronically HCV‐infected patients who had achieved SVR by DAA therapy and whose serum Mac‐2 binding protein glycosylation isomer (M2BPGi) levels at baseline (before DAA therapy) were ≥2.0 the cut‐off index (COI). We defined patients with M2BPGi levels <1.76 and ≥1.76 COI at 2 years after the end of treatment (EOT) as the regression (R, n = 69) and nonregression (NR, n = 40) groups, respectively.
Results
Multivariate analyses revealed that the Ang‐2 level at baseline and the Ang‐2 level, albumin–bilirubin score, and FIB‐4 index at 24 weeks after the EOT were significantly associated with regression of M2BPGi‐based liver fibrosis. Receiver operating characteristic curve analyses showed that the Ang‐2 level at 24 weeks after the EOT had the largest area under the curve values (0.859). The same results were obtained even when the serum M2BPGi levels were aligned by propensity score matching and in patients with advanced M2BPGi‐based liver fibrosis: M2BPGi levels ≥3.3 COI at baseline.
Conclusions
The serum Ang‐2 level at 24 weeks after the EOT is a feasible predictor of regression of M2BPGi‐based liver fibrosis after achieving SVR by DAA therapy.</description><identifier>ISSN: 1386-6346</identifier><identifier>EISSN: 1872-034X</identifier><identifier>DOI: 10.1111/hepr.13823</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc</publisher><subject>Angiopoietin ; angiopoietin‐2 (Ang‐2) ; Antiviral agents ; Bilirubin ; Eradication ; Fibrosis ; Glycosylation ; Hepatitis C ; hepatitis C virus eradication ; Liver ; Mac‐2 binding protein glycosylation isomer (M2BPGi) ; Patients ; predictor of regression of fibrosis</subject><ispartof>Hepatology research, 2022-11, Vol.52 (11), p.919-927</ispartof><rights>2022 The Japan Society of Hepatology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3543-9271feca329745282a9a7160946b3970feb5b29fcb7649044ae741338f6a98db3</citedby><cites>FETCH-LOGICAL-c3543-9271feca329745282a9a7160946b3970feb5b29fcb7649044ae741338f6a98db3</cites><orcidid>0000-0002-2473-6966</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fhepr.13823$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fhepr.13823$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids></links><search><creatorcontrib>Suzuki, Takanori</creatorcontrib><creatorcontrib>Matsuura, Kentaro</creatorcontrib><creatorcontrib>Nagura, Yoshihito</creatorcontrib><creatorcontrib>Ogawa, Shintaro</creatorcontrib><creatorcontrib>Fujiwara, Kei</creatorcontrib><creatorcontrib>Nojiri, Shunsuke</creatorcontrib><creatorcontrib>Watanabe, Takehisa</creatorcontrib><creatorcontrib>Kataoka, Hiromi</creatorcontrib><creatorcontrib>Tanaka, Yasuhito</creatorcontrib><title>Serum angiopoietin‐2 levels predict regression of Mac‐2 binding protein glycosylation isomer‐based liver fibrosis after hepatitis C virus eradication by direct‐acting antiviral agents</title><title>Hepatology research</title><description>Aim
It is desirable to identify predictors of regression of liver fibrosis after achieving a sustained virologic response (SVR) by direct‐acting antiviral agents (DAAs) to antihepatitis C virus (HCV) therapy. Here, we retrospectively investigated the serum angiopoietin‐2 (Ang‐2) level as a predictive indicator of regression of liver fibrosis after successful HCV eradication by DAA therapy.
Methods
The study subjects were recruited from a historical cohort of 109 chronically HCV‐infected patients who had achieved SVR by DAA therapy and whose serum Mac‐2 binding protein glycosylation isomer (M2BPGi) levels at baseline (before DAA therapy) were ≥2.0 the cut‐off index (COI). We defined patients with M2BPGi levels <1.76 and ≥1.76 COI at 2 years after the end of treatment (EOT) as the regression (R, n = 69) and nonregression (NR, n = 40) groups, respectively.
Results
Multivariate analyses revealed that the Ang‐2 level at baseline and the Ang‐2 level, albumin–bilirubin score, and FIB‐4 index at 24 weeks after the EOT were significantly associated with regression of M2BPGi‐based liver fibrosis. Receiver operating characteristic curve analyses showed that the Ang‐2 level at 24 weeks after the EOT had the largest area under the curve values (0.859). The same results were obtained even when the serum M2BPGi levels were aligned by propensity score matching and in patients with advanced M2BPGi‐based liver fibrosis: M2BPGi levels ≥3.3 COI at baseline.
Conclusions
The serum Ang‐2 level at 24 weeks after the EOT is a feasible predictor of regression of M2BPGi‐based liver fibrosis after achieving SVR by DAA therapy.</description><subject>Angiopoietin</subject><subject>angiopoietin‐2 (Ang‐2)</subject><subject>Antiviral agents</subject><subject>Bilirubin</subject><subject>Eradication</subject><subject>Fibrosis</subject><subject>Glycosylation</subject><subject>Hepatitis C</subject><subject>hepatitis C virus eradication</subject><subject>Liver</subject><subject>Mac‐2 binding protein glycosylation isomer (M2BPGi)</subject><subject>Patients</subject><subject>predictor of regression of fibrosis</subject><issn>1386-6346</issn><issn>1872-034X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp90c1u1DAQAOAIUYnScuEJLHFBSCn-2zg-olVLkYqo-JG4WY4zDq689mI7i3LjEXgj3oUnwdtw6gFf7JE-z4w9TfOc4AtS1-tvsE8XhPWUPWpOSS9oixn_-rieWd-1HePdk-ZpzncYE4EpP21-f4I075AOk4v76KC48OfnL4o8HMBntE8wOlNQgilBzi4GFC16r809GlwYXZiqigVcQJNfTMyL1-UIXY47SBUOOsOIvDtAQtYNKWaXkbalhrXfikuNt-jg0pwRJF0rrhmGBY0ugSk1iTblWEqH4irUHukJQsnnzYnVPsOzf_tZ8-Xq8vP2ur358Pbd9s1Na9iGs1ZSQSwYzagUfEN7qqUWpMOSdwOTAlsYNgOV1gyi4xJzrkFwwlhvOy37cWBnzcs1b33r9xlyUTuXDXivA8Q5K9pJKTu8wbTSFw_oXZxTqN0pKqjkmHDJqnq1KlP_Iyewap_cTqdFEayOs1THWar7WVZMVvzDeVj-I9X15e3H9c5f_CGphg</recordid><startdate>202211</startdate><enddate>202211</enddate><creator>Suzuki, Takanori</creator><creator>Matsuura, Kentaro</creator><creator>Nagura, Yoshihito</creator><creator>Ogawa, Shintaro</creator><creator>Fujiwara, Kei</creator><creator>Nojiri, Shunsuke</creator><creator>Watanabe, Takehisa</creator><creator>Kataoka, Hiromi</creator><creator>Tanaka, Yasuhito</creator><general>Wiley Subscription Services, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2473-6966</orcidid></search><sort><creationdate>202211</creationdate><title>Serum angiopoietin‐2 levels predict regression of Mac‐2 binding protein glycosylation isomer‐based liver fibrosis after hepatitis C virus eradication by direct‐acting antiviral agents</title><author>Suzuki, Takanori ; Matsuura, Kentaro ; Nagura, Yoshihito ; Ogawa, Shintaro ; Fujiwara, Kei ; Nojiri, Shunsuke ; Watanabe, Takehisa ; Kataoka, Hiromi ; Tanaka, Yasuhito</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3543-9271feca329745282a9a7160946b3970feb5b29fcb7649044ae741338f6a98db3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Angiopoietin</topic><topic>angiopoietin‐2 (Ang‐2)</topic><topic>Antiviral agents</topic><topic>Bilirubin</topic><topic>Eradication</topic><topic>Fibrosis</topic><topic>Glycosylation</topic><topic>Hepatitis C</topic><topic>hepatitis C virus eradication</topic><topic>Liver</topic><topic>Mac‐2 binding protein glycosylation isomer (M2BPGi)</topic><topic>Patients</topic><topic>predictor of regression of fibrosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Suzuki, Takanori</creatorcontrib><creatorcontrib>Matsuura, Kentaro</creatorcontrib><creatorcontrib>Nagura, Yoshihito</creatorcontrib><creatorcontrib>Ogawa, Shintaro</creatorcontrib><creatorcontrib>Fujiwara, Kei</creatorcontrib><creatorcontrib>Nojiri, Shunsuke</creatorcontrib><creatorcontrib>Watanabe, Takehisa</creatorcontrib><creatorcontrib>Kataoka, Hiromi</creatorcontrib><creatorcontrib>Tanaka, Yasuhito</creatorcontrib><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Hepatology research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Suzuki, Takanori</au><au>Matsuura, Kentaro</au><au>Nagura, Yoshihito</au><au>Ogawa, Shintaro</au><au>Fujiwara, Kei</au><au>Nojiri, Shunsuke</au><au>Watanabe, Takehisa</au><au>Kataoka, Hiromi</au><au>Tanaka, Yasuhito</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum angiopoietin‐2 levels predict regression of Mac‐2 binding protein glycosylation isomer‐based liver fibrosis after hepatitis C virus eradication by direct‐acting antiviral agents</atitle><jtitle>Hepatology research</jtitle><date>2022-11</date><risdate>2022</risdate><volume>52</volume><issue>11</issue><spage>919</spage><epage>927</epage><pages>919-927</pages><issn>1386-6346</issn><eissn>1872-034X</eissn><abstract>Aim
It is desirable to identify predictors of regression of liver fibrosis after achieving a sustained virologic response (SVR) by direct‐acting antiviral agents (DAAs) to antihepatitis C virus (HCV) therapy. Here, we retrospectively investigated the serum angiopoietin‐2 (Ang‐2) level as a predictive indicator of regression of liver fibrosis after successful HCV eradication by DAA therapy.
Methods
The study subjects were recruited from a historical cohort of 109 chronically HCV‐infected patients who had achieved SVR by DAA therapy and whose serum Mac‐2 binding protein glycosylation isomer (M2BPGi) levels at baseline (before DAA therapy) were ≥2.0 the cut‐off index (COI). We defined patients with M2BPGi levels <1.76 and ≥1.76 COI at 2 years after the end of treatment (EOT) as the regression (R, n = 69) and nonregression (NR, n = 40) groups, respectively.
Results
Multivariate analyses revealed that the Ang‐2 level at baseline and the Ang‐2 level, albumin–bilirubin score, and FIB‐4 index at 24 weeks after the EOT were significantly associated with regression of M2BPGi‐based liver fibrosis. Receiver operating characteristic curve analyses showed that the Ang‐2 level at 24 weeks after the EOT had the largest area under the curve values (0.859). The same results were obtained even when the serum M2BPGi levels were aligned by propensity score matching and in patients with advanced M2BPGi‐based liver fibrosis: M2BPGi levels ≥3.3 COI at baseline.
Conclusions
The serum Ang‐2 level at 24 weeks after the EOT is a feasible predictor of regression of M2BPGi‐based liver fibrosis after achieving SVR by DAA therapy.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc</pub><doi>10.1111/hepr.13823</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-2473-6966</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1386-6346 |
| ispartof | Hepatology research, 2022-11, Vol.52 (11), p.919-927 |
| issn | 1386-6346 1872-034X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2699960502 |
| source | Wiley Online Library Journals Frontfile Complete |
| subjects | Angiopoietin angiopoietin‐2 (Ang‐2) Antiviral agents Bilirubin Eradication Fibrosis Glycosylation Hepatitis C hepatitis C virus eradication Liver Mac‐2 binding protein glycosylation isomer (M2BPGi) Patients predictor of regression of fibrosis |
| title | Serum angiopoietin‐2 levels predict regression of Mac‐2 binding protein glycosylation isomer‐based liver fibrosis after hepatitis C virus eradication by direct‐acting antiviral agents |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T21%3A07%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20angiopoietin%E2%80%902%20levels%20predict%20regression%20of%20Mac%E2%80%902%20binding%20protein%20glycosylation%20isomer%E2%80%90based%20liver%20fibrosis%20after%20hepatitis%20C%20virus%20eradication%20by%20direct%E2%80%90acting%20antiviral%20agents&rft.jtitle=Hepatology%20research&rft.au=Suzuki,%20Takanori&rft.date=2022-11&rft.volume=52&rft.issue=11&rft.spage=919&rft.epage=927&rft.pages=919-927&rft.issn=1386-6346&rft.eissn=1872-034X&rft_id=info:doi/10.1111/hepr.13823&rft_dat=%3Cproquest_cross%3E2729401493%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2729401493&rft_id=info:pmid/&rfr_iscdi=true |